Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Org Lett ; 3(12): 1905-8, 2001 Jun 14.
Artigo em Inglês | MEDLINE | ID: mdl-11405741

RESUMO

[see reaction]. The reaction of activated alkynes with carbonyl compounds in the presence of a catalytic amount of a nucleophile leads to enol-protected functionalized propargyl alcohols and 1,3-dioxolane compounds by way of a mild carbon-carbon bond formation reaction.

2.
Org Lett ; 2(22): 3513-5, 2000 Nov 02.
Artigo em Inglês | MEDLINE | ID: mdl-11082022

RESUMO

[reaction: see text] A remarkable exo-facial template effect exercised by a 2, 3-O-isopropylidene protective group is the key for the entire 2, 3-trans stereoselectivity observed in the allylsilane addition promoted by BF(3).OEt(2) to 2,3-O-isopropylidene-protected pyrrolidines.


Assuntos
Pirrolidinas/síntese química , Desenho de Fármacos , Iminas , Indicadores e Reagentes , Conformação Molecular , Estrutura Molecular , Estereoisomerismo
4.
Anesthesiology ; 82(3): 734-40; discussion 27A, 1995 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-7879941

RESUMO

BACKGROUND: Ropivacaine is a new amide local anesthetic, having therapeutic properties similar to those of bupivacaine but with a wider margin of safety. Bupivacaine is probably the most commonly used drug in obstetric epidural analgesia, even though laboratory studies have suggested that pregnancy increases the cardiotoxicity of bupivacaine but not of other local anesthetics. The current study was designed to reevaluate, in a random and blinded fashion, the systemic toxicity of bupivacaine and ropivacaine in nonpregnant and pregnant sheep. METHODS: Chronically prepared nonpregnant and pregnant ewes were randomized to receive an intravenous infusion of ropivacaine or bupivacaine at a constant rate of 0.5 mg.kg-1.min-1 until circulatory collapse. The investigators were blinded to the identity of local anesthetic. Heart rate, arterial blood pressure, and cardiac rhythm were monitored throughout the study. Arterial blood samples were obtained before infusion and at the onset of toxic manifestations, which appeared in the following sequence: convulsions, hypotension, apnea, and circulatory collapse. Serum drug concentrations and protein binding were determined. Blood pH and gas tensions were measured. RESULTS: There were no significant differences between non-pregnant and pregnant animals in the doses or serum concentrations of either drug required to elicit toxic manifestations. In nonpregnant animals, similar doses and serum concentrations of ropivacaine and bupivacaine were associated with the onset of convulsions and circulatory collapse. In pregnant ewes, greater doses of ropivacaine as compared to bupivacaine were required to produce convulsions (7.5 +/- 0.5 vs. 5.0 +/- 0.6 mg.kg-1) and circulatory collapse (12.9 +/- 0.8 vs. 8.5 +/- 1.2 mg.kg-1). The corresponding serum concentrations of ropivacaine were similar to those of bupivacaine. Pregnancy did not affect the serum protein binding of either drug. The proportion of animals manifesting a malignant ventricular arrhythmia as the terminal event was similar among all groups. CONCLUSIONS: The systemic toxicity of ropivacaine or bupivacaine is not enhanced by gestation in sheep. This is in contrast to an earlier study in which the cardiotoxicity of bupivacaine was enhanced during ovine pregnancy. Greater doses of ropivacaine, as compared to bupivacaine, are needed to produce toxic manifestations in pregnant animals.


Assuntos
Amidas/toxicidade , Bupivacaína/toxicidade , Animais , Apneia/induzido quimicamente , Pressão Sanguínea/efeitos dos fármacos , Relação Dose-Resposta a Droga , Método Duplo-Cego , Feminino , Frequência Cardíaca/efeitos dos fármacos , Hemodinâmica/efeitos dos fármacos , Concentração de Íons de Hidrogênio , Hipotensão/induzido quimicamente , Gravidez/efeitos dos fármacos , Ropivacaina , Convulsões/induzido quimicamente , Ovinos , Distribuição Tecidual
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...